Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1981 1
1984 1
1987 1
1992 1
1994 5
1995 3
1996 3
1997 5
1998 5
1999 3
2000 1
2001 5
2002 4
2003 3
2004 6
2005 1
2006 2
2007 6
2008 2
2009 2
2010 3
2011 2
2012 3
2013 3
2014 5
2015 7
2016 6
2017 6
2018 5
2019 9
2020 11
2021 10
2022 13
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

142 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Primary Bone Lymphoma"
Page 1
Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder.
Melani C, Jaffe ES, Wilson WH. Melani C, et al. Blood. 2020 Apr 16;135(16):1344-1352. doi: 10.1182/blood.2019000933. Blood. 2020. PMID: 32107539 Free PMC article. Review.
Clinically, LYG universally involves the lungs with other common extranodal sites, including skin, central nervous system, liver, and kidneys. Nodal and/or bone marrow involvement is extremely rare and, if present, suggests an alternative diagnosis. ...Given the underlying …
Clinically, LYG universally involves the lungs with other common extranodal sites, including skin, central nervous system, liver, and kidney …
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Moskowitz AJ, Shah G, Schöder H, Ganesan N, Drill E, Hancock H, Davey T, Perez L, Ryu S, Sohail S, Santarosa A, Galasso N, Neuman R, Liotta B, Blouin W, Kumar A, Lahoud O, Batlevi CL, Hamlin P, Straus DJ, Rodriguez-Rivera I, Owens C, Caron P, Intlekofer AM, Hamilton A, Horwitz SM, Falchi L, Joffe E, Johnson W, Lee C, Palomba ML, Noy A, Matasar MJ, Pongas G, Salles G, Vardhana S, Sanin BW, von Keudell G, Yahalom J, Dogan A, Zelenetz AD, Moskowitz CH. Moskowitz AJ, et al. J Clin Oncol. 2021 Oct 1;39(28):3109-3117. doi: 10.1200/JCO.21.01056. Epub 2021 Jun 25. J Clin Oncol. 2021. PMID: 34170745 Free PMC article. Clinical Trial.
PURPOSE: We conducted a phase II study evaluating pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) (ClinicalTrials.gov identifier: NCT0361 …
PURPOSE: We conducted a phase II study evaluating pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) as sec …
Primary Mediastinal B-Cell Lymphoma: A 2021 Update on Genetics, Diagnosis, and Novel Therapeutics.
Ahmed Z, Afridi SS, Shahid Z, Zamani Z, Rehman S, Aiman W, Khan M, Mir MA, Awan FT, Anwer F, Iftikhar R. Ahmed Z, et al. Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):e865-e875. doi: 10.1016/j.clml.2021.06.012. Epub 2021 Jun 24. Clin Lymphoma Myeloma Leuk. 2021. PMID: 34330673 Review.
Primary mediastinal large B-cell lymphoma (PMBCL) is an aggressive B-cell lymphoma arising from thymic B-cells having clinicopathologic features distinct from systemic diffuse large B-cell lymphoma (DLBCL). PMBCL comprises 2% to 4% of all non-Hodgkin …
Primary mediastinal large B-cell lymphoma (PMBCL) is an aggressive B-cell lymphoma arising from thymic B-cells having c …
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.
Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, Mougiakakos D, Frölich L, Ackermann J, Bücklein V, Blumenberg V, Schmidt C, Jallades L, Fehse B, Faul C, Karschnia P, Weigert O, Dreyling M, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge W, Ayuk F, Bachy E, Salles G, Jain MD, Subklewe M. Rejeski K, et al. Blood. 2021 Dec 16;138(24):2499-2513. doi: 10.1182/blood.2020010543. Blood. 2021. PMID: 34166502 Free PMC article.
In this multicenter analysis, we studied patterns of hematopoietic reconstitution and evaluated potential predictive markers in 258 patients receiving axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) for relapsed/refractory large B-cell lymphoma. We …
In this multicenter analysis, we studied patterns of hematopoietic reconstitution and evaluated potential predictive markers in 258 patients …
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Martinez-Prieto M, Han X, Tiwari R, Salles G, Maziarz RT. Schuster SJ, et al. Lancet Oncol. 2021 Oct;22(10):1403-1415. doi: 10.1016/S1470-2045(21)00375-2. Epub 2021 Sep 10. Lancet Oncol. 2021. PMID: 34516954 Clinical Trial.
BACKGROUND: In the primary analysis of the pivotal JULIET trial of tisagenlecleucel, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, the best overall response rate was 52% and the complete response rate was 40% in 93 evaluable adult patients with re …
BACKGROUND: In the primary analysis of the pivotal JULIET trial of tisagenlecleucel, an autologous anti-CD19 chimeric antigen recepto …
Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment.
Maitre E, Cornet E, Troussard X. Maitre E, et al. Am J Hematol. 2019 Dec;94(12):1413-1422. doi: 10.1002/ajh.25653. Epub 2019 Oct 31. Am J Hematol. 2019. PMID: 31591741 Free article. Review.
DISEASE OVERVIEW: Hairy cell leukemia (HCL) and HCL-like disorders, including HCL variant (HCL-V) and splenic diffuse red pulp lymphoma (SDRPL), are a very heterogeneous group of mature lymphoid B-cell disorders. ...The use of PNA followed by rituximab represents an altern …
DISEASE OVERVIEW: Hairy cell leukemia (HCL) and HCL-like disorders, including HCL variant (HCL-V) and splenic diffuse red pulp lymphoma …
Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.
Trabolsi A, Arumov A, Schatz JH. Trabolsi A, et al. Blood Cancer J. 2024 Feb 8;14(1):27. doi: 10.1038/s41408-024-00997-w. Blood Cancer J. 2024. PMID: 38331870 Free PMC article. Review.
Despite recent advances in frontline therapy for diffuse large B-cell lymphoma (DLBCL), at least a third of those diagnosed still will require second or further lines for relapsed or refractory (rel/ref) disease. ...CD19-directed chimeric antigen receptor T-cell (CA …
Despite recent advances in frontline therapy for diffuse large B-cell lymphoma (DLBCL), at least a third of those diagnosed still wil …
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma.
Epperla N, Kumar A, Abutalib SA, Awan FT, Chen YB, Gopal AK, Holter-Chakrabarty J, Kekre N, Lee CJ, Lekakis L, Lin Y, Mei M, Nathan S, Nastoupil L, Oluwole O, Phillips AA, Reid E, Rezvani AR, Trotman J, Zurko J, Kharfan-Dabaja MA, Sauter CS, Perales MA, Locke FL, Carpenter PA, Hamadani M. Epperla N, et al. Transplant Cell Ther. 2023 Sep;29(9):548-555. doi: 10.1016/j.jtct.2023.06.012. Epub 2023 Jul 5. Transplant Cell Ther. 2023. PMID: 37419325 Free article.
Autologous hematopoietic cell transplantation (auto-HCT) has long been the standard approach for patients with relapsed/refractory (R/R) chemosensitive diffuse large B cell lymphoma (DLBCL). ...The RAND-modified Delphi method was used to generate 20 consensus statem …
Autologous hematopoietic cell transplantation (auto-HCT) has long been the standard approach for patients with relapsed/refractory (R …
Primary Central Nervous System Lymphoma.
Sinicrope K, Batchelor T. Sinicrope K, et al. Neurol Clin. 2018 Aug;36(3):517-532. doi: 10.1016/j.ncl.2018.04.008. Neurol Clin. 2018. PMID: 30072069 Review.
Primary central nervous system lymphoma (PCNSL) is an aggressive form of non-Hodgkin lymphoma restricted to the central nervous system. ...Extent of disease evaluation for newly diagnosed PCNSL patients includes brain imaging, eye examination, cerebrospinal f …
Primary central nervous system lymphoma (PCNSL) is an aggressive form of non-Hodgkin lymphoma restricted to the central …
Protein arginine methyltransferase 1 is a therapeutic vulnerability in multiple myeloma.
Nguyen HP, Le AQ, Liu E, Cesarano A, DiMeo F, Perna F, Kapur R, Walker BA, Tran NT. Nguyen HP, et al. Front Immunol. 2023 Aug 4;14:1239614. doi: 10.3389/fimmu.2023.1239614. eCollection 2023. Front Immunol. 2023. PMID: 37600810 Free PMC article.
Multiple myeloma (MM) is a devastating plasma cell malignancy characterized by the expansion of aberrant monoclonal plasma cells in the bone marrow, leading to severe clinical manifestations and poor prognosis, particularly in relapsed/refractory cases. ...Treatment …
Multiple myeloma (MM) is a devastating plasma cell malignancy characterized by the expansion of aberrant monoclonal plasma cells in the b …
142 results